Title |
Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016.
|
---|---|
Published in |
Eurosurveillance, March 2016
|
DOI | 10.2807/1560-7917.es.2016.21.11.30168 |
Pubmed ID | |
Authors |
Catharine Chambers, Danuta M Skowronski, Suzana Sabaiduc, Anne Luise Winter, James A Dickinson, Gaston De Serres, Jonathan B Gubbay, Steven J Drews, Christine Martineau, Alireza Eshaghi, Mel Krajden, Nathalie Bastien, Yan Li |
Abstract |
Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2015/16 vaccine effectiveness (VE) against influenza A(H1N1)pdm09 viruses. Adjusted VE showed significant protection of 64% (95% confidence interval (CI): 44-77%) overall and 56% (95%CI: 26-73%) for adults between 20 and 64 years-old against medically attended, laboratory-confirmed A(H1N1)pdm09 illness. Among the 67 A(H1N1)pdm09-positive specimens that were successfully sequenced, 62 (> 90%) belonged to the emerging genetic 6B.1 subclade, defined by S162N (potential gain of glycosylation) and I216T mutations in the haemagglutinin protein. Findings from the Canadian SPSN indicate that the 2015/16 northern hemisphere vaccine provided significant protection against A(H1N1)pdm09 illness despite genetic evolution in circulating viruses. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 2% |
Unknown | 42 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 21% |
Researcher | 7 | 16% |
Student > Ph. D. Student | 7 | 16% |
Student > Bachelor | 6 | 14% |
Professor > Associate Professor | 2 | 5% |
Other | 3 | 7% |
Unknown | 9 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 33% |
Nursing and Health Professions | 5 | 12% |
Veterinary Science and Veterinary Medicine | 2 | 5% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Agricultural and Biological Sciences | 1 | 2% |
Other | 6 | 14% |
Unknown | 13 | 30% |